Dr. John Cush RheumNow
7 years 3 months ago
RheumNow Podcast is UP! Discussions of MTX stomatitis, Loading doses, PPD Shortage, infection risk from steroids or THR/TKR and more. Watch it here>> https://t.co/8koj2HG4RC or listen in on iTunes or SoundCloud >> https://t.co/0EXaXq2l7G
The July issue of the Journal of the American Academy of Dermatology reports that patients with psoriasis are frequent users of complementary and alternative medicines (CAMs) largely because of disatisfaction with traditional medications.The National Psoriasis Foundation commissioned a survey of patients on CAMs use and patients' perceptions.The survey was sent to 100,927 NPF members and 219 completed it.
Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com.
Dr. John Cush RheumNow
7 years 3 months ago
FDA has announced that on July 25th it will hold an Arthritis Advisory Committee Meeting to discuss Boehringer Ingelheims application for Nintedanib use in systemic sclerosis-associated interstitial lung disease (SSc-ILD) https://t.co/z4uLJ8hdyX
JAMA reports that there is a trend of increasing mortality from falls in older US adults between 2000 to 2016 and that mortality rates are increased with increasing age.
MMWR has published the outcomes from the Georgia Lupus Registry between 2002 and 2016, finding that black women were not only more likely to die from lupus than white lupus patients; but they died on average 13 years earlier (mean age 51.8 and 52.3 years, respectively) than whites (mean age 64.4 and 65.0 years, respectively).
Black women with lupus were 3.34 times more likely to die than black women in the general population, while white women
Dr. John Cush RheumNow
7 years 3 months ago
What’s next in biosimilars? Visit RheumNow to listen to experts discuss this and more in "Therapeutic Update: Biosimilars in Rheumatology," a video series sponsored by Sandoz, Inc. https://t.co/1vmnEJqOSi #sponsored
Dr. John Cush RheumNow
7 years 3 months ago
Metanalysis of 3954 studies, 20 RCTs examined MTX toxicity and found the prevalence of alopecia to be 1- 4.9% and the prevalence of stomatitis to be between 5.7-8% https://t.co/LHbAYvV71X
Dr. John Cush RheumNow
7 years 3 months ago
A Western Norway study of GCA (1972–2012) compared 792 GCA (528 Bx-verified) to 2577 matched controls. There were no differences in overall survival (p=0.41). GCA had higher risk of CV death (HR 1.31) but lower risk of cancer deaths (HR 0.56). https://t.co/oBx2kBTyrZ
The American College of Physicians (ACP) is encouraged by the Trump administration’s executive order to improve transparency of health care costs. ACP firmly believes that increasing health care transparency is critical in providing quality, affordable, and accessible health care coverage to patients who need it the most.
It is estimated that up to 50% of patients with idiopathic inflammatory myopathy will be complicated by interstitial lung disease, and having ILD may impart a poor prognosis. A recent review of the Johns Hopkins myositis-related ILD cohort has shown that azathioprine and mycophenolate mofetil use is associated improved lung function and less prednisone use.
Dr. John Cush RheumNow
7 years 3 months ago
The BMS merger with Celgene to be hastened by BMS divesting itself from Otezla. https://t.co/Ew0sg9YSaZ
Dr. John Cush RheumNow
7 years 3 months ago
ORAL Strategy, 216 or 18.8% received the Zostvax vaccine. Overall, 18 patients (1.6%) developed HZ (vaccinated=3; non-vaccinated=15). HZ IRs (95% CI) were 1.1 (0.3, 2.9), 2.3 (1.0, 4.6), and 1.7 (0.6, 3.7) for tofa monotherapy, tofa+MTX, & ADA+MTX, resp. https://t.co/SE5ANjRHB8
Dr. John Cush RheumNow
7 years 3 months ago
795 RA patients from the GIRRCS cohort 3 year study found that maintaining remission reduced the incidence of subclinical atherosclerosis by three-quarters (OR = 0.25; P = .001). (87% were on MTX; 60% on biologics) #EULAR2019 ABST# OP0090 https://t.co/RvRcXsDnKs

